Istvan Petak: What we know about cancer biology and immunology in clinical practice
Istvan Petak shared on Linkedin:
”Hello, Amazing Best-of-ASCO Conference 2024! I was deeply honored to be invited to share the latest groundbreaking abstracts selected by ASCO about ‘Developmental Therapeutics – IO and molecular and tumor biology‘ and to participate in the expert panel to discuss cases together.
It is my passion to speak about what we can next implement what we know about cancer biology and immunology in clinical practice. Exciting abstracts covered the successful use of CAR-T in sarcomas, targeting T-Reg cells in gastric cancer to overcome resistance to immunotherapy, oncolytic adenovirus therapy that traps TGF-Beta to provoke ‘autoimmunity’ against cancer after the virus-induced inflammation and the results of a PDL-1 inhibitor in TMB-H cancer across multiple tumor types.
The conclusion is that immunotherapies can achieve excellent, durable responses, but we must search for better solutions for a more personalized selection of the right therapy for our patients.
We must move ahead and use multidimensional parameters for better prediction and harness more of the biological knowledge we already have.
Thank you, Adrian Udrea and all organizers, for the kind invitation and warm hospitality. Thank you, Medisprof, for hosting this fantastic event where international speakers can share. Udrea and his team have built a world-class cancer center. The Medisprof cancer center not only provides state-of-the-art treatments but also puts a lot of emphasis on the psychological and spiritual well-being of its patients. Udrea not only has deep experience in oncology but also a big heart.
I also thank the outstanding presentations of the other expert speakers: Gabriela Ilie, E. Gabriela Chiorean, Razvan Andrei Popescu, Evangelia Razis, Magdolna Dank, Mateo Elena-Daniela, Santiago Cabezas-Camarero, Arantzazu Barquín García, Alberto Jacobo Cunquero Tomás, Rob Rutledge.
Thank you, American Society of Clinical Oncology (ASCO), for uniting us worldwide against cancer.
Source: Istvan Petak/Linkedin
Dr. Istvan Petak specialises in precision oncology and molecular pharmacology of targeted therapies. He is the founder and CEO of Genomate Health, Inc. Cambridge, MA, founder and board director of Oncompass Medicine, Budapest, HU, and adjunct professor at the Department of Pharmaceutical Sciences at the University of Illinois at Chicago (UIC).
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023